Owens & Minor reports preliminary Q2 GAAP net loss $0.42-0.46/share, adj. EPS $0.32-$0.36; reaffirms FY guidance

ACCENDRA HEALTH INC/VA/

2024-Q2 EPS reported -$0.70 revenue$5,283,686,000

Revenue $2,651-$2,671M; GAAP net loss per share $(0.42)-$(0.46); adjusted EPS $0.32-$0.36.
One-time income tax charge of $17M ($0.22/share) from transfer pricing dispute; expected cash payment $30-$35M in H2 2024.
Full-year 2024 outlook reaffirmed: revenue $10.5-$10.9B, adj. EBITDA $550-$590M, adj. EPS $1.40-$1.70.
Adjusted EBITDA $123-$127M; operating cash flow $111-$116M; net debt reduction $68-$71M.
Full Q2 results to be released on August 2, 2024, before NYSE open.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.